Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy
Status:
Completed
Trial end date:
2020-01-19
Target enrollment:
Participant gender:
Summary
The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic
stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by
intravenous infusion for 6 hours. Groups with the lowest dose will start. When it is
determined that each dose is safe and tolerable, the next higher dose will be given to the
next group.